Rapid Communication - Journal of Clinical Respiratory Medicine (2025) Volume 9, Issue 1

Pulmonary Hypertension and Vascular Disorders: A Clinical Overview

Sanjay H. Chotirmall ^*

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

*Corresponding Author:

Sanjay H. Chotirmall
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
E-mail: schotirmall@ntu.edu.sg

Received: 1-Mar-2025, Manuscript No. aajcrm-25-167784; Editor assigned: 4-Mar-2025, PreQC No. aajcrm-25-167784 (PQ) Reviewed:17-Mar-2025, QC No. aajcrm-25-167784 Revised:24-Mar-2025, Manuscript No. aajcrm-25-167784; Published:31-Mar-2025, DOI: 10.35841/ aajcrm - 9.1.252

Citation: Chotirmall S. Pulmonary hypertension and vascular disorders: A clinical overview. J Clin Resp Med. 2025;9(1):252

Introduction

Pulmonary hypertension (PH) is a complex and progressive condition characterized by elevated blood pressure within the pulmonary arteries, leading to increased workload on the right side of the heart and, ultimately, right heart failure. It is not a single disease but a spectrum of disorders classified into five distinct groups based on underlying causes, including left heart disease, chronic lung diseases, and thromboembolic events [1].

The pathophysiology of PH involves vascular remodeling, endothelial dysfunction, and vasoconstriction, all contributing to increased pulmonary vascular resistance. These changes compromise oxygen exchange and cardiac output, resulting in symptoms such as dyspnea, fatigue, chest pain, and syncope [2].

Vascular disorders associated with PH include pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), and vasculitides like systemic sclerosis. PAH, often idiopathic or linked to connective tissue diseases, is marked by narrowed and stiff pulmonary vessels. CTEPH, a potentially curable form of PH, arises from unresolved pulmonary emboli that cause persistent vascular obstruction [3].

Early diagnosis through echocardiography, right heart catheterization, and advanced imaging is crucial. Treatment strategies aim at reducing pulmonary pressure and improving quality of life [4].

These include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogs and in selected cases, surgical interventions such as pulmonary endarterectomy [5].

Conclusion

Pulmonary hypertension remains a serious condition with significant morbidity and mortality. A multidisciplinary approach involving cardiologists, pulmonologists, and rheumatologists is essential to manage this challenging disorder and improve patient outcomes.

References

1. Ghigna MR, Dorfmüller P. Pulmonary vascular disease and pulmonary hypertension. Diagn Histopathol. 2019;25(8):304-12.

Indexed at, Google Scholar, Cross Ref

2. Edwards WD, Edwards JE. Clinical primary pulmonary hypertension: Three pathologic types. Circ. 1977;56(5):884-8.

Indexed at, Google Scholar, Cross Ref

3. Cheever KH. An overview of pulmonary arterial hypertension: Risks, pathogenesis, clinical manifestations, and management. Eur J Cardiovasc Nurs. 2005;20(2):108-16.

Indexed at, Google Scholar, Cross Ref

4. Machado RF, Gladwin MT. Pulmonary hypertension in hemolytic disorders: Pulmonary vascular disease: The global perspective. Chest. 2010;137(6):30S-8S.

Indexed at, Google Scholar, Cross Ref

5. Ghamra ZW, Dweik RA. Primary pulmonary hypertension: An overview of epidemiology and pathogenesis. Cleve Clin J Med. 2003;70(1):S2.

Indexed at, Google Scholar, Cross Ref